Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
Table 3
Unadjusted summaries of measured variables pre- and posttreatment.
Placebo ()
Atorvastatin ()
Pre
Post
%
Pre
Post
%
oxLDLβ 2GPI u/L
Mean ± SD
2.6 ± 0.5
2.9 ± 0.5
11.5%
2.6 ± 0.7
1.9 ± 0.5
−26.9%
Median ± IQR
2.6 ± 0.7
2.8 ± 1.0
7.7%
2.8 ± 1.1
1.9 ± 0.7
−32.1%
CRP µg/mL
Mean ± SD
3.0 ± 2.7
3.4 ± 2.3
13.3%
6.6 ± 8.4
1.9 ± 1.2
−71.2%
Median ± IQR
2.4 ± 2.7
2.8 ± 3.5
16.7%
2.9 ± 6.0
2.0 ± 2.0
−31.0%
SAA µg/mL
Mean ± SD
13.5 ± 9.5
3.8 ± 2.4
−71.9%
14.5 ± 11.2
5.3 ± 4.8
−63.4%
Median ± IQR
16.2 ± 15.8
3.4 ± 4.9
−79.0%
9.9 ± 20.5
3.3 ± 5.2
−66.7%
µM
Mean ± SD
31.6 ± 25.0
27.0 ± 16.9
−14.6%
20.2 ± 10.2
18.9 ± 9.6
−6.4%
Median ± IQR
21.8 ± 31.2
23.6 ± 24.9
8.3%
20.4 ± 19.0
17.6 ± 12.5
−13.7%
µM
Mean ± SD
9.2 ± 4.9
9.6 ± 4.9
4.3%
13.1 ± 6.4
11.3 ± 4.2
−13.7%
Median ± IQR
6.6 ± 9.1
9.1 ± 4.4
37.9%
10.5 ± 10.0
10.5 ± 5.2
0.0%
NT Nm
Mean ± SD
557.2 ± 1729.4
307.2 ± 673.1
−44.9%
266.6 ± 593.5
143.1 ± 177.1
−46.3%
Median ± IQR
15.9 ± 47.1
111.1 ± 151.8
598.7%
18.7 ± 84.0
78.5 ± 164.2
319.8%
TG mmol/L
Mean ± SD
1.23 ± 0.61
1.17 ± 0.47
−4.9%
1.26 ± 0.78
1.07 ± 0.62
−15.1%
Median ± IQR
1.15 ± 1.08
1.10 ± 0.90
−4.3%
1.00 ± 1.08
0.95 ± 0.95
−5.0%
CHO mmol/L
Mean ± SD
5.43 ± 0.96
5.50 ± 1.02
1.3%
4.36 ± 1.21
3.23 ± 0.62
−25.9%
Median ± IQR
5.15 ± 1.55
5.70 ± 1.35
10.7%
4.30 ± 1.70
3.35 ± 0.90
−22.1%
LDL mmol/L
Mean ± SD
2.95 ± 0.67
3.16 ± 0.53
7.1%
2.55 ± 1.05
1.49 ± 0.57
−41.6%
Median ± IQR
2.80 ± 1.20
3.10 ± 1.00
10.7%
2.70 ± 1.10
1.40 ± 0.78
−48.1%
HDL mmol/L
Mean ± SD
1.86 ± 0.58
1.81 ± 0.46
−2.7%
1.20 ± 0.27
1.28 ± 0.21
6.7%
Median ± IQR
1.75 ± 0.55
1.70 ± 0.65
−2.9%
1.25 ± 0.45
1.30 ± 0.35
4.0%
PON U/L
Mean ± SD
101.36 ± 16.38
92.65 ± 23.18
−8.6%
78.31 ± 17.52
94.44 ± 18.40
20.6%
Median ± IQR
106.80 ± 13.22
103.38 ± 45.53
−3.2%
78.06 ± 30.03
104.52 ± 33.76
33.9%
PON/HDL
Mean ± SD
58.29 ± 19.43
55.80 ± 16.21
−4.3%
70.92 ± 28.20
79.26 ± 21.46
11.8%
Median ± IQR
52.85 ± 29.09
59.46 ± 21.90
12.5%
62.88 ± 28.25
78.96 ± 32.08
25.6%
IMT CC mm
Mean ± SD
0.058 ± 0.013
0.057 ± 0.014
−1.7%
0.057 ± 0.010
0.059 ± 0.010
3.5%
Median ± IQR
0.055 ± 0.018
0.050 ± 0.020
−9.1%
0.058 ± 0.015
0.060 ± 0.015
3.4%
%: percentage difference; oxLDLβ 2GPI: oxidised low density lipoprotein-beta 2-glycoprotein-1 complex; CRP: C-reactive protein; SAA: serum amyloid A; : nitrate; : nitrite; NT: nitrotyrosine; TG: triglycerides; CHO: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; PON: paraoxonase; IMT CC: intima media thickness of common carotid artery; SD: standard deviation; IQR: interquartile range.
We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.
